Lv1
36 积分 2025-03-13 加入
P19.01 RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
1个月前
已完结
Design and Analysis of Phase I Clinical Trials
1个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
1个月前
已完结
Successful Adoptive Immunotherapy with Lymphokine-activated Killer Cells in the Treatment of Medulloblastoma Disseminated via Cerebrospinal Fluid
2个月前
已完结
IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion
2个月前
已完结
TGF-β-activated NK-92 cell therapy for esophageal squamous cell carcinoma
2个月前
已完结
Natural Born Killers: Harnessing NK Cells to Treat Cancer
2个月前
已完结
Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis
3个月前
已关闭
Severity Scoring of Atopic Dermatitis: The SCORAD Index
3个月前
已关闭
Severity Scoring of Atopic Dermatitis: The SCORAD Index
3个月前
已完结
皖公网安备34019202002308
